INR 83.7
(-0.46%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 1.72 Billion INR | 85.17% |
2022 | 856.66 Million INR | -45.36% |
2021 | 1.56 Billion INR | 20.51% |
2020 | 1.28 Billion INR | 67.84% |
2019 | 779.98 Million INR | 9.64% |
2018 | 711.89 Million INR | 4.02% |
2017 | 684.5 Million INR | 5.21% |
2016 | 650.95 Million INR | 2.92% |
2015 | 625.79 Million INR | 26.51% |
2014 | 496.1 Million INR | -1.02% |
2013 | 530.2 Million INR | 50.96% |
2012 | 369.1 Million INR | 62.67% |
2011 | 324.5 Million INR | 200.6% |
2010 | 68.1 Million INR | -40.89% |
2009 | 453.45 Million INR | 138.99% |
2008 | 125.44 Million INR | 597.68% |
2007 | 119.35 Million INR | -105.53% |
2006 | -675.44 Million INR | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | 516.18 Million INR | 4.6% |
2023 Q2 | 368.26 Million INR | 29.18% |
2023 Q3 | 546.37 Million INR | 48.36% |
2023 Q4 | 483.8 Million INR | -11.45% |
2023 Q1 | 285.08 Million INR | 52.6% |
2023 FY | - INR | 85.17% |
2022 Q4 | 186.81 Million INR | -14.08% |
2022 Q3 | 217.42 Million INR | -27.0% |
2022 FY | - INR | -45.36% |
2022 Q1 | 154.58 Million INR | -60.13% |
2022 Q2 | 297.83 Million INR | 92.67% |
2021 FY | - INR | 20.51% |
2021 Q2 | 420.26 Million INR | -7.5% |
2021 Q3 | 348.13 Million INR | -17.16% |
2021 Q1 | 454.31 Million INR | 127.08% |
2021 Q4 | 387.74 Million INR | 11.38% |
2020 Q2 | 483.23 Million INR | 73.2% |
2020 Q1 | 279 Million INR | 38.66% |
2020 FY | - INR | 67.84% |
2020 Q4 | 200.06 Million INR | -40.02% |
2020 Q3 | 333.57 Million INR | -30.97% |
2019 Q3 | 199.06 Million INR | 11.39% |
2019 FY | - INR | 9.64% |
2019 Q4 | 201.21 Million INR | 1.08% |
2019 Q1 | 196.11 Million INR | -11.98% |
2019 Q2 | 178.7 Million INR | -8.88% |
2018 Q4 | 222.79 Million INR | 15.64% |
2018 FY | - INR | 4.02% |
2018 Q3 | 192.65 Million INR | 14.03% |
2018 Q1 | 122.52 Million INR | -30.64% |
2018 Q2 | 168.95 Million INR | 37.89% |
2017 Q2 | 201.24 Million INR | 81.29% |
2017 FY | - INR | 5.21% |
2017 Q3 | 190.55 Million INR | -5.31% |
2017 Q4 | 176.66 Million INR | -7.29% |
2017 Q1 | 111 Million INR | 0.0% |
2016 FY | - INR | 2.92% |
2015 FY | - INR | 26.51% |
2014 FY | - INR | -1.02% |
2013 FY | - INR | 50.96% |
2012 Q1 | - INR | 0.0% |
2012 Q3 | - INR | 0.0% |
2012 Q4 | - INR | 0.0% |
2012 FY | - INR | 62.67% |
2012 Q2 | - INR | 0.0% |
2011 FY | - INR | 200.6% |
2010 FY | - INR | -40.89% |
2009 FY | - INR | 138.99% |
2008 FY | - INR | 597.68% |
2007 FY | - INR | -105.53% |
2006 FY | - INR | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Sigachi Industries Limited | 883.39 Million INR | -95.377% |
Ind-Swift Limited | 1.06 Billion INR | -62.051% |
Bajaj HealthCare Limited | 406.23 Million INR | -324.863% |
Sakar Healthcare Limited | 393.26 Million INR | -338.875% |
Aurobindo Pharma Limited | 61.78 Billion INR | 97.207% |
Innova Captab Limited | 1.66 Billion INR | -3.455% |
Divi's Laboratories Limited | 25.43 Billion INR | 93.213% |
AstraZeneca Pharma India Limited | 2.35 Billion INR | 26.767% |
Mankind Pharma Limited | 28.09 Billion INR | 93.857% |
Sequent Scientific Limited | 549.8 Million INR | -213.924% |
Wanbury Limited | 985.49 Million INR | -75.137% |
Laurus Labs Limited | 8 Billion INR | 78.442% |
Nectar Lifesciences Limited | 1.53 Billion INR | -12.397% |
Glenmark Life Sciences Limited | 6.86 Billion INR | 74.851% |
Alembic Limited | 1.11 Billion INR | -54.608% |
Hikal Limited | 2.69 Billion INR | 35.891% |
Alembic Pharmaceuticals Limited | 9.61 Billion INR | 82.053% |
Neuland Laboratories Limited | 4.74 Billion INR | 63.65% |
J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 81.511% |
Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 84.785% |
IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 33.785% |
Themis Medicare Limited | 562.6 Million INR | -206.778% |
RPG Life Sciences Limited | 1.28 Billion INR | -34.682% |
Zydus Lifesciences Limited | 56.22 Billion INR | 96.93% |
Lupin Limited | 36.96 Billion INR | 95.331% |
Amrutanjan Health Care Limited | 681.59 Million INR | -153.222% |
Wockhardt Limited | 1.08 Billion INR | -59.811% |
Vaishali Pharma Limited | 31.71 Million INR | -5342.761% |
Aarti Pharmalabs Limited | 3.9 Billion INR | 55.851% |
Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -433.591% |
Jubilant Pharmova Limited | 8 Billion INR | 78.442% |
FDC Limited | 3.38 Billion INR | 49.017% |
Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 98.045% |
Kilitch Drugs (India) Limited | 287.42 Million INR | -500.488% |
Eris Lifesciences Limited | 6.98 Billion INR | 75.296% |
Venus Remedies Limited | 711.8 Million INR | -142.477% |
ZIM Laboratories Limited | 462.09 Million INR | -273.505% |
Bliss GVS Pharma Limited | 1.47 Billion INR | -16.695% |
Par Drugs and Chemicals Limited | 228.17 Million INR | -656.42% |
Caplin Point Laboratories Limited | 6.18 Billion INR | 72.089% |
Shilpa Medicare Limited | 2.58 Billion INR | 33.309% |
Albert David Limited | 1.04 Billion INR | -65.096% |
Ajanta Pharma Limited | 12.56 Billion INR | 86.264% |
Hester Biosciences Limited | 539.47 Million INR | -219.935% |
Suven Pharmaceuticals Limited | 4.67 Billion INR | 63.098% |
Solara Active Pharma Sciences Limited | -2.82 Billion INR | 161.163% |
Gufic Biosciences Limited | 1.48 Billion INR | -16.58% |
Windlas Biotech Limited | 781.72 Million INR | -120.789% |
Procter & Gamble Health Limited | 3.07 Billion INR | 43.86% |
Aarey Drugs & Pharmaceuticals Limited | 45.16 Million INR | -3721.441% |
Mangalam Drugs & Organics Limited | 174.94 Million INR | -886.564% |
Granules India Limited | 8.6 Billion INR | 79.94% |
Aarti Drugs Limited | 3.24 Billion INR | 46.871% |
Bal Pharma Limited | 345.59 Million INR | -399.42% |
Alkem Laboratories Limited | 24.19 Billion INR | 92.867% |
Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 98.753% |
Lincoln Pharmaceuticals Limited | 1.34 Billion INR | -28.484% |
Medicamen Biotech Limited | 245.66 Million INR | -602.578% |
Unichem Laboratories Limited | 742.35 Million INR | -132.497% |
Bafna Pharmaceuticals Limited | 114.58 Million INR | -1406.292% |
Biofil Chemicals and Pharmaceuticals Limited | 12.99 Million INR | -13180.656% |
Valiant Laboratories Limited | 12.73 Million INR | -13448.583% |
Orchid Pharma Limited | 1.41 Billion INR | -21.616% |
Medico Remedies Limited | 129.09 Million INR | -1236.975% |
Ind-Swift Laboratories Limited | 6.86 Billion INR | 74.846% |
Ipca Laboratories Limited | 13.29 Billion INR | 87.022% |
Brooks Laboratories Limited | 41.72 Million INR | -4036.201% |
Syncom Formulations (India) Limited | 430.27 Million INR | -301.127% |
Piramal Enterprises Limited | -3.86 Billion INR | 144.701% |
Torrent Pharmaceuticals Limited | 35 Billion INR | 95.07% |
NATCO Pharma Limited | 18.79 Billion INR | 90.817% |
Suven Life Sciences Limited | -992.78 Million INR | 273.851% |
Krebs Biochemicals & Industries Limited | -82.72 Million INR | 2186.325% |
Strides Pharma Science Limited | 3.76 Billion INR | 54.154% |
Indoco Remedies Limited | 2.64 Billion INR | 34.797% |
Alpa Laboratories Limited | 229.96 Million INR | -650.542% |
Lasa Supergenerics Limited | -65.08 Million INR | 2752.05% |
Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 146.254% |